Company Description

Nuvig Therapeutics is a clinical-stage biotechnology company pioneering precisely engineered Fc-based therapeutics to redefine the treatment of chronic inflammatory and autoimmune diseases. The company’s lead candidate is NVG-2089, an engineered Fc fragment that is designed to mimic the binding of sialylated IgG to type II Fc receptors.